Related Experiment Video
Updated: Apr 16, 2026

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing
Saravana P Selvanathan1, Garrett T Graham1, Hayriye V Erkizan1
1Department of Oncology and Pediatrics, Georgetown University, Washington, DC 20057;
Abstract:
The synthesis and processing of mRNA, from transcription to translation initiation, often requires splicing of intragenic material. The final mRNA composition varies based on proteins that modulate splice site selection. EWS-FLI1 is an Ewing sarcoma (ES) oncoprotein with an interactome that we demonstrate to have multiple partners in spliceosomal complexes. We evaluate the effect of EWS-FLI1 on posttranscriptional gene regulation using both exon array and RNA-seq. Genes that potentially regulate oncogenesis, including CLK1, CASP3, PPFIBP1, and TERT, validate as alternatively spliced by EWS-FLI1. In a CLIP-seq experiment, we find that EWS-FLI1 RNA-binding motifs most frequently occur adjacent to intron-exon boundaries. EWS-FLI1 also alters splicing by directly binding to known splicing factors including DDX5, hnRNP K, and PRPF6. Reduction of EWS-FLI1 produces an isoform of γ-TERT that has increased telomerase activity compared with wild-type (WT) TERT. The small molecule YK-4-279 is an inhibitor of EWS-FLI1 oncogenic function that disrupts specific protein interactions, including helicases DDX5 and RNA helicase A (RHA) that alters RNA-splicing ratios. As such, YK-4-279 validates the splicing mechanism of EWS-FLI1, showing alternatively spliced gene patterns that significantly overlap with EWS-FLI1 reduction and WT human mesenchymal stem cells (hMSC). Exon array analysis of 75 ES patient samples shows similar isoform expression patterns to cell line models expressing EWS-FLI1, supporting the clinical relevance of our findings. These experiments establish systemic alternative splicing as an oncogenic process modulated by EWS-FLI1. EWS-FLI1 modulation of mRNA splicing may provide insight into the contribution of splicing toward oncogenesis, and, reciprocally, EWS-FLI1 interactions with splicing proteins may inform the splicing code.
Insights
Ewing sarcoma oncoprotein EWS-FLI1 drives cancer by altering messenger RNA (mRNA) splicing. Inhibiting EWS-FLI1 with YK-4-279 normalizes splicing patterns, offering a potential therapeutic strategy for Ewing sarcoma.
Area of Science:
- Molecular Biology
- Oncology
- Gene Regulation
Background:
- Messenger RNA (mRNA) splicing is crucial for gene expression, with splice site selection modulated by various proteins.
- Ewing sarcoma (ES) is driven by the EWS-FLI1 oncoprotein, which interacts with spliceosomal complexes.
- Dysregulation of posttranscriptional gene regulation, including alternative splicing, is implicated in oncogenesis.
Purpose of the Study:
- To investigate the impact of the EWS-FLI1 oncoprotein on mRNA splicing and posttranscriptional gene regulation in Ewing sarcoma.
- To identify specific genes and splicing factors modulated by EWS-FLI1.
- To evaluate the therapeutic potential of targeting EWS-FLI1-mediated splicing alterations.
Main Methods:
- Exon array and RNA-sequencing (RNA-seq) were employed to analyze gene expression and splicing patterns.
- CLIP-seq experiments were conducted to identify RNA-binding motifs of EWS-FLI1.
- Protein-protein interaction studies were performed to assess EWS-FLI1 binding to splicing factors.
- The effect of the EWS-FLI1 inhibitor YK-4-279 on splicing was evaluated.
- Analysis of patient samples was performed using exon arrays.
Main Results:
- EWS-FLI1 significantly alters the splicing of genes involved in oncogenesis, such as CLK1, CASP3, PPFIBP1, and TERT.
- EWS-FLI1 binds to splicing factors like DDX5, hnRNP K, and PRPF6, directly influencing splicing.
- Reduction of EWS-FLI1 leads to altered TERT splicing, impacting telomerase activity.
- The inhibitor YK-4-279 mimics the splicing alterations observed upon EWS-FLI1 reduction.
- Splicing patterns in ES patient samples resemble those in cell line models expressing EWS-FLI1.
Conclusions:
- Systemic alternative splicing is an oncogenic process driven by EWS-FLI1 in Ewing sarcoma.
- EWS-FLI1's modulation of mRNA splicing contributes to oncogenesis.
- Targeting EWS-FLI1 interactions with splicing machinery, potentially via inhibitors like YK-4-279, represents a viable therapeutic strategy.
Related Concept Videos
RNA Splicing
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
Pre-mRNA Processing: RNA Splicing
What is Gene Expression?

